Literature DB >> 31698426

TFH lymphomas: the times they aza-changin'?

David M Weinstock1, Steven M Horwitz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31698426      PMCID： PMC6839955          DOI： 10.1182/blood.2019002806

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

Authors:  François Lemonnier; Jehan Dupuis; Pierre Sujobert; Olivier Tournillhac; Morgane Cheminant; Clémentine Sarkozy; Laura Pelletier; Ambroise Marçais; Cyrielle Robe; Virginie Fataccioli; Corinne Haioun; Olivier Hermine; Philippe Gaulard; Richard Delarue
Journal:  Blood       Date:  2018-10-02       Impact factor: 22.113

2.  A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

Authors:  Jennifer E Amengual; Renee Lichtenstein; Jennifer Lue; Ahmed Sawas; Changchun Deng; Emily Lichtenstein; Karen Khan; Laine Atkins; Aishling Rada; Hye A Kim; Codruta Chiuzan; Matko Kalac; Enrica Marchi; Lorenzo Falchi; Mark A Francescone; Lawrence Schwartz; Serge Cremers; Owen A O'Connor
Journal:  Blood       Date:  2017-11-15       Impact factor: 22.113

3.  Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.

Authors:  Owen A O'Connor; Lorenzo Falchi; Jennifer K Lue; Enrica Marchi; Cristina Kinahan; Ahmed Sawas; Changchun Deng; Francesca Montanari; Jennifer E Amengual; Hye A Kim; Aishling M Rada; Karen Khan; Alice T Jacob; Michelle Malanga; Mark M Francescone; Renu Nandakumar; Craig R Soderquist; David C Park; Govind Bhagat; Bin Cheng; Alberto Risueño; Daniel Menezes; Andrei R Shustov; Lubomir Sokol; Luigi Scotto
Journal:  Blood       Date:  2019-10-24       Impact factor: 22.113

Review 4.  How I treat the peripheral T-cell lymphomas.

Authors:  Alison J Moskowitz; Matthew A Lunning; Steven M Horwitz
Journal:  Blood       Date:  2014-03-10       Impact factor: 22.113

5.  The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.

Authors:  Enrica Marchi; Kelly M Zullo; Jennifer E Amengual; Matko Kalac; Danielle Bongero; Christine M McIntosh; Laura K Fogli; Maura Rossi; Pier L Zinzani; Stefano A Pileri; Pier P Piccaluga; Fabio Fuligni; Luigi Scotto; Owen A O'Connor
Journal:  Br J Haematol       Date:  2015-07-20       Impact factor: 6.998

6.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

7.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Authors:  Adam C Palmer; Peter K Sorger
Journal:  Cell       Date:  2017-12-14       Impact factor: 41.582

8.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Authors:  Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper
Journal:  Lancet       Date:  2018-12-04       Impact factor: 79.321

Review 9.  Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways.

Authors:  Mathijs Willemsen; Myrurgia Abdul Hamid; Bjorn Winkens; Axel Zur Hausen
Journal:  Blood Cancer J       Date:  2018-01-17       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.